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This project has been supported by an unrestricted grant from Abbvie, Spain. The Lp(a) seems to act as an acute-phase reactant. However, unlike traditional lipid metabolism, which is effectively modulated by treatment of the disease (2, 7), the effects of therapy on metabolism of Lp(a) in patients with RA remain unclear. This may be explained in part by the fact that genetic factors have a large impact on the variation of Lp(a) levels (8) .
Better control of inflammation and disease activity in patients with RA has been achieved by the use of biologic therapies. However, there have been few studies that evaluate the impact of these new therapies on Lp(a) in RA (9, 10) . This aspect is of particular interest because it has been observed that Lp(a) levels are higher in individuals with elevated interleukin-6 (IL-6) serum concentrations, as this proinflammatory cytokine increases the transcriptional activity of the apo(a) gene LPA (11) .
Taking into account all of these considerations, the purpose of the present study was to evaluate the plasma concentrations of Lp(a) in Spanish patients with RA on biologic therapy attending Rheumatology outpatient clinics. These patients were enrolled in the CARdiovascular in rheuMAtology (CARMA), a 10-year prospective cohort study designed to determine the cardiovascular mortality risk in patients with chronic inflammatory rheumatic diseases, including those with RA.
MATERIAL AND METHODS

Study design
Cross-sectional analysis from the baseline visit of a 10-year prospective follow-up study CARMA. In this study, a cohort of patients with chronic inflammatory rheumatic diseases, including those with RA, were compared with another non-inflammatory cohort (12) .
Patient recruitment
Patients diagnosed with RA at sixty-seven Rheumatology Units selected from Spanish National Health System hospitals participated in the study. 
Variables and operative definitions
Lp(a) plasma concentrations were considered the primary endpoint. All biochemistry determinations were made after an overnight fast and they were analyzed according to the methodology and reproducibility level of each participant institution.
The cohort with RA was evaluated following international protocols, including standardized definitions and validated questionnaires. All patients included in this study were continuously and systematically evaluated on-line and, to verify the quality of the information, in situ data monitoring was performed in 15% of randomly selected patients.
Treatment of RA, as an explanatory variable, was classified into four categories: no biologic therapy, anti-tumor necrosis factor (TNF) therapy, treatment with tocilizumab (TCZ), and other biological therapies (rituximab or abatacept).
Other variables analyzed were: (1) obesity (body mass index ≥ 30 kg/m2) and main physical activity during working hours (low activity: sitting most of the time; moderate activity: standing most of the time and with little movement or effort; intense activity: walking most of the time or performing tasks that require high physical activity); (2) traditional (classic) CV risk factors (hypertension, dyslipidemia, obesity, smoking, diabetes and family history of ischemic heart disease); (3) Hyperlipoproteinemia(a) was defined by a serum Lp(a) concentration > 50mg/dL.
Statistical analysis
Variables were described according to their typology and distribution. Categorical variables were described using frequencies and percentages. Differences between groups were compared using chi-squared tests. Continuous variables that followed a normal distribution were described using the mean and standard deviation (SD) and the differences between groups were assessed using ANOVA tests. Non-normally distributed variables were described with the median and interquartile range (IQR) and differences between groups were assessed with the Kruskal-Wallis non-parametric test.
In all of the analyses a p-value ≤0.05 was considered statistically significant.
Given the asymmetric nature of the outcome variable (Lp(a)), a logarithmic transformation was performed and the model was adjusted using multivariate linear regression. To reduce variability in the methods of measurement of Lp(a) across the participating hospitals, mixed linear multivariate regression models were constructed with robust variance estimators using the hospital as a cluster for variable estimation. Table 2 . Total cholesterol and TG were significantly higher in patients treated with TCZ than in the rest of patients with RA. However, no significant differences in the atherogenic index 
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were observed. By contrast, TCZ-treated patients exhibited statistically significant lower plasma concentrations of Lp(a) than the rest of RA patients included in the other groups. Of note, only a small percentage of TCZ-treated patients had hyperlipoproteinemia(a) ( Table 2) . No other significant differences were found among groups. Log Lp(a). CI: confidence interval; TNF: tumor necrosis factor; LDL-c: low-density lipoprotein cholesterol; CRP: C-reactive protein; DMARD: Disease-modifying antirheumatic drugs.
DISCUSSION
The results from the present study show that TCZ-treated RA patients followed-up at rheumatology-out-patient clinics have lower plasma concentrations of Lp(a) than RA patients not treated with biologics.
The relationship between alterations in conventional lipid profiles and inflammation in patients with RA is well known (14) . However, despite the fact that Lp(a) exerts atherogenic and prothrombotic effects (3), the presence of hyperlipoproteinemia(a) in RA has not received sufficient attention (2, 15) . This may be due in part to the lack of an effective pharmacological treatment for hyperlipoproteinemia(a) (16) , and also Due to the presence of chronic inflammation, the relationship between CV disease and lipid levels in patients with RA appears to be different from that observed in the general population (18) . In this regard, lipoprotein abnormalities described in RA patients improve with effective anti-rheumatic treatment as a result of the reduction in inflammation (7). Nevertheless, the mechanisms involved in this process are far from being completely understood. Although some studies have shown that methotrexate alone, or in combination with an anti-TNF, may lead to a significant reduction of Lp(a) levels in RA (19) , a former study of our group disclosed that Lp(a) levels remain consistently elevated in RA despite antirheumatic therapy (including glucocorticoids, conventional DMARDs and anti-TNF therapy) (2).
The introduction of biologic therapies targeting specific inflammatory mediators different from anti-TNF agents has been an important step forward in the management of RA. The results of the present study did not show statistically significant differences in the Lp(a) levels between RA patients treated with anti-TNF therapy and those not receiving biologic therapy. Unlike these biologic agents, it is worth noting that TCZ therapy was associated with low plasma concentrations of Lp(a) in our patients with RA, and that this association remained statistically significant after adjusting for potentially confounding factors.
To the best of our knowledge, this association has only been assessed in two studies (9, 10) . In this regard, Schultz et al. Anti-rheumatic therapies increase TC, HDL-c, LDL-c and TG to variable degrees in patients with RA (18) . This is especially true for patients treated with the anti-IL-6-receptor TCZ. Nevertheless, in the majority of TCZ-treated patients there is no increase in the atherogenic index (TC/HDL-c), and patients experience a good response to treatment with lipid lowering agents (21) . In keeping with that, the present study disclosed a significant increase of TC and TG levels in RA patients undergoing TCZ therapy. LDL-c and HDL-c were also slightly elevated when compared with RA patients who were not treated with biologic therapy, although the differences did not reach statistical significance. Moreover, as previously reported, no significant differences in the atherogenic index were found.
Additional findings from our study were the positive association between Lp(a) and LDL-c and the negative association between Lp(a) and TG. These findings have also previously been described (22) . The positive correlation between the LDL-c and Lp(a) could be explained, in part, because the value of the concentration of Lp(a) was included in the value of LDL-c. This is also consistent with the fact that every particle of Lp(a) contains a particle of LDL. The inverse correlation between the serum concentration of triglycerides and Lp(a) has also been described in several observational studies, though the underlying mechanism has not been elucidated (22, 23) . It has been M A N U S C R I P T
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14 postulated that a common mechanism related to the metabolic syndrome could be implicated in lowering Lp(a) in patients with hypertriglyceridemia (24) .
Despite the fact that TCZ is associated with an increase in lipids, the use of this biologic agent has a favorable effect on lipid metabolism. With respect to this, TCZ improves the functionality of HDL-cholesterol. This is due to beneficial effects on its structural composition, moving from proinflammatory to anti-inflammatory particles (10, 25) .As mentioned before, this study shows that TCZ displays low plasma concentrations of Lp(a), which is increasingly recognized as a risk factor signaling the development of coronary heart disease (4). In this regard, a study of 1,153 individuals revealed that Lp(a) levels were increased in those with elevated IL-6 serum concentrations (26) . In the same study transcriptomic analyses revealed that the commonly found IL-6 response genes correlated with apo(a) gene LPA expression in human liver in vivo. Moreover, the authors found that TCZ inhibited IL-6-induced expression of LPA and specifically inhibited LPA promoter activity in human hepatocytes on a molecular level (26) .
Therefore, the association between IL-6 inhibition and lower levels of Lp(a) appears to be regulated by genetic mechanisms, specifically to regulation of the genetic expression of apo(a), the main protein of this lipoprotein.
The strong association between elevated Lp(a) levels and increased CV disease/risk suggests that the former, like elevated LDL-c, is causally associated with premature CV disease (27) . Since recent studies have shown a high frequency of carotid plaques in RA patients included in the category of moderate CV risk we think that Lp(a) assessment might be considered in the study of patients with chronic inflammatory diseases (29) , not only in those patients with a high CV risk, familial hypercholesterolemia, or a family history of premature CV disease.
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There are a number of potential limitations in our study. First, the subgroup of RA patients undergoing TCZ therapy was relatively small. Nevertheless, the significant association between TCZ and lower plasma concentrations of Lp(a) was reinforced after adjusting for potential confounding factors. Second, we could not send all of the samples to a single reference laboratory to determine the lipid parameters. Therefore,
we performed a statistical analysis that attempted to minimize the impact of possible variations in the results from the different centers. Finally, another point of potential concern is the cross-sectional nature of our analysis. Nevertheless, our results support an effect of the IL-6 blockade on Lp(a) that makes TCZ different from anti-TNF therapy.
CONCLUSIONS
In conclusion, the results of the CARMA cohort confirm the claim that the use of anti- ischemic heart disease; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal anti-inflammatory drugs; ACE: angiotensin converting enzyme; ARBs:
angiotensin II receptor blockers;
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